Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up.
Saved in:
| Title: | Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up. |
|---|---|
| Authors: | Veerapandiyan, Aravindhan1 (AUTHOR), Bourke, John2 (AUTHOR), Soslow, Jonathan H.3 (AUTHOR), Day, John W.4 (AUTHOR), McDonald, Craig M.5 (AUTHOR), Mendell, Jerry R.6 (AUTHOR), Zaidman, Craig M.7 (AUTHOR), Mason, Stefanie6 (AUTHOR), Meng, Jianfeng6 (AUTHOR), Vivien, Mark6 (AUTHOR), Murphy, Alexander P.8 (AUTHOR), Wandel, Christoph9 (AUTHOR), Richardson, James6 (AUTHOR) jrichardson@sarepta.com |
| Source: | Cardiology & Therapy. Jul2026, p1-17. 17p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
